10/19/2005 5:13:06 PM
SAN DIEGO--(BUSINESS WIRE)--March 23, 2005--Genetronics Biomedical Corporation (AMEX:GEB), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that its subsidiary, Genetronics, Inc., has been granted another patent for a vascular application of its technology, namely U.S. Patent Number 6,865,416, entitled "Electrically Induced Vessel Vasodilation." The patent adds to Genetronics' position as a pioneer in the use of electroporation therapy, without drugs, to achieve vasodilation.
Electroporation refers to the application of electrical pulses to a target tissue to temporarily increase the permeability of biological membranes. This patent was granted for the invention that brief electrical pulses of relatively high field strength applied to blood vessels cause a widening of the inner diameter (the lumen) of the treated vessels. This allows for enhanced blood flow while lowering local blood pressure. This procedure may have the potential to be beneficially applied to patients who suffer from partially or totally blocked arteries or veins, either by administering electrical field pulses by themselves or in conjunction with angioplasty.
comments powered by